Literature DB >> 17219753

Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies.

Lilly Q Yue1.   

Abstract

Propensity score analysis is a versatile statistical method used mainly in observational studies for improving treatment comparison by adjusting for up to a relatively large number of potentially confounding covariates. Recently, there has been an increased interest in applying this method to nonrandomized medical device clinical studies. In the application of the methodology, some statistical and regulatory issues arise in both study design and analysis of study results, such as the need for pre-specifying clinically relevant covariates to be measured, appropriate patient populations, and the essential elements of statistical analysis, planning sample size in the context of propensity score methodology, handling missing covariates in generating propensity scores, and assessing the success of the propensity score method by evaluating treatment group overlap in terms of the distributions of propensity scores. In this paper, the advantages and limitations of this methodology will be revisited, and the above issues will be discussed and illustrated with examples from a regulatory perspective.

Entities:  

Mesh:

Year:  2007        PMID: 17219753     DOI: 10.1080/10543400601044691

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  14 in total

1.  Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.

Authors:  Renato De Natale; Antoine Lafuma; Gilles Berdeaux
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

2.  The effectiveness of inpatient rehabilitation in the acute postoperative phase of care after transtibial or transfemoral amputation: study of an integrated health care delivery system.

Authors:  Margaret G Stineman; Pui L Kwong; Jibby E Kurichi; Janet A Prvu-Bettger; W Bruce Vogel; Greg Maislin; Barbara E Bates; Dean M Reker
Journal:  Arch Phys Med Rehabil       Date:  2008-10       Impact factor: 3.966

3.  Randomized clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and overcoming bias.

Authors:  Allan I Pack; Ulysses J Magalang; Bhajan Singh; Samuel T Kuna; Brendan T Keenan; Greg Maislin
Journal:  Sleep       Date:  2021-02-12       Impact factor: 5.849

4.  To RCT or not to RCT? Depends on the question. A response to McEvoy et al.

Authors:  Allan I Pack; Ulysses J Magalang; Bhajan Singh; Samuel T Kuna; Brendan T Keenan; Greg Maislin
Journal:  Sleep       Date:  2021-04-09       Impact factor: 5.849

5.  Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Authors:  Stephan Matthaei; Matthew Reaney; Chantal Mathieu; Claes-Göran Ostenson; Thure Krarup; Bruno Guerci; Jacek Kiljanski; Helmut Petto; David Bruhn; Michael Theodorakis
Journal:  Diabetes Ther       Date:  2012-06-20       Impact factor: 2.945

6.  Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.

Authors:  Melissa H Roberts; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-03-22

7.  Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database.

Authors:  Philippe Denis; Antoine Lafuma; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2008-06

8.  Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Authors:  Chantal Mathieu; Claes-Göran Ostenson; Stephan Matthaei; Matthew Reaney; Thure Krarup; Bruno Guerci; Jacek Kiljański; Carole Salaun-Martin; Hélène Sapin; Michael Theodorakis
Journal:  Diabetes Ther       Date:  2013-09-10       Impact factor: 2.945

9.  Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Authors:  Claes-Göran Ostenson; Stephan Matthaei; Matthew Reaney; Thure Krarup; Bruno Guerci; Jacek Kiljanski; Carole Salaun-Martin; Hélène Sapin; David Bruhn; Chantal Mathieu; Michael Theodorakis
Journal:  Diabetes Metab Syndr Obes       Date:  2013-04-26       Impact factor: 3.168

10.  Probabilistic data linkage: a case study of comparative effectiveness in COPD.

Authors:  Christopher M Blanchette; Mitch Dekoven; Ajita P De; Melissa Roberts
Journal:  Drugs Context       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.